{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:12:33Z","timestamp":1790626353823,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clim.2017.04.015","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T18:30:34Z","timestamp":1493404234000},"page":"77-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats"],"prefix":"10.1016","volume":"184","author":[{"given":"Smadar","family":"Gertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Mahagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-9308","authenticated-orcid":false,"given":"Gidi","family":"Karmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Watad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.04.015_bb0005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2017.04.015_bb0010","doi-asserted-by":"crossref","first-page":"ii87","DOI":"10.1136\/ard.61.suppl_2.ii87","article-title":"Cartilage destruction in rheumatoid arthritis","volume":"61","author":"Gay","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.04.015_bb0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-3083.1985.tb01884.x","article-title":"T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones","volume":"22","author":"Holmdahl","year":"1985","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clim.2017.04.015_bb0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.1780300708","article-title":"Histopathology of arthritis induced in rats by active immunization to mycobacterial antigens or by systemic transfer of T lymphocyte lines. A light and electron microscopic study of the articular surface using cationized ferritin","volume":"30","author":"Stanescu","year":"1987","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.04.015_bb0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197509112931101","article-title":"Predominantly T-cell infiltrate in rheumatoid synovial membranes","volume":"293","author":"Van Boxel","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.04.015_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-065X.2010.00951.x","article-title":"Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors","volume":"238","author":"Zhu","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2017.04.015_bb0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2017.04.015_bb0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2474-14-332","article-title":"Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies","volume":"14","author":"Berhan","year":"2013","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.clim.2017.04.015_bb0045","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1060028013512790","article-title":"Tofacitinib: the First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis","volume":"47","author":"Vyas","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clim.2017.04.015_bb0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.clim.2017.04.015_bb0055","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.04.015_bb0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/ard.2007.076430","article-title":"Utility of animal models for identification of potential therapeutics for rheumatoid arthritis","volume":"67","author":"Hegen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.04.015_bb0065","doi-asserted-by":"crossref","first-page":"569068","DOI":"10.1155\/2011\/569068","article-title":"Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy","volume":"2011","author":"Bolon","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.clim.2017.04.015_bb0070","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s13075-015-0866-0","article-title":"Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice","volume":"17","author":"Llop-Guevara","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2017.04.015_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S62879","article-title":"Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies","volume":"7","author":"Boyce","year":"2016","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.clim.2017.04.015_bb0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clim.2017.04.015_bb0085","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2017.04.015_bb0090","first-page":"568","article-title":"Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials","volume":"15","author":"Menter","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.clim.2017.04.015_bb0095","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/ecco-jcc\/jjw107","article-title":"Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis","volume":"10","author":"Panes","year":"2016","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.clim.2017.04.015_bb0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.berh.2014.10.017","article-title":"Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety","volume":"28","author":"Meier","year":"2014","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.clim.2017.04.015_bb0105","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.04.015_bb0110","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2017.04.015_bb0115","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2365","article-title":"Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis","volume":"10","author":"Milici","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2017.04.015_bb0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jbspin.2015.09.002","article-title":"JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells","volume":"83","author":"Wu","year":"2016","journal-title":"Joint, Bone, Spine"},{"key":"10.1016\/j.clim.2017.04.015_bb0125","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.4049\/jimmunol.1300514","article-title":"JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T cells and Th17 cells","volume":"192","author":"Park","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.04.015_bb0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/ard.2007.080341","article-title":"Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis","volume":"67","author":"Yamada","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2017.04.015_bb0135","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1038\/mtna.2012.37","article-title":"Specific Jak3 downregulation in lymphocytes impairs gammac cytokine signal transduction and alleviates antigen-driven inflammation in vivo","volume":"1","author":"Gomez-Valades","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.clim.2017.04.015_bb0140","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616306003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616306003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T03:52:22Z","timestamp":1535860342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616306003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"alternative-id":["S1521661616306003"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.04.015","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}